首页 | 本学科首页   官方微博 | 高级检索  
     


Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia
Authors:Nicola Gökbuget  Hervé Dombret  Sebastian Giebel  Monika Brüggemann  Michael Doubek  Robin Foa  Dieter Hoelzer  Christopher Kim  Giovanni Martinelli  Elena Parovichnikova  Josep Maria Ribera  Marieke Schoonen  Catherine Tuglus  Gerhard Zugmaier  Renato Bassan
Affiliation:1. University Hospital, Goethe University, Frankfurt, Germany;2. Hôpital Saint-Louis, University Paris Diderot, Paris, France;3. Maria Sklodowska-Curie Institute—Oncology Center, Gliwice, Poland;4. University Hospital Schleswig-Holstein, Kiel, Germany;5. University Hospital and CEITEC Masaryk University, Brno, Czech Republic;6. ‘Sapienza’ University of Rome, Rome, Italy;7. J.W. Goethe University Hospital, Frankfurt, Germany;8. Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA;9. Policlinico S Orsola Istituto Seragnoli, Bologna, Italy;10. National Research Center for Hematology, Moscow, Russia;11. ICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Barcelona, Spain;12. Centre for Observational Research, Amgen Ltd, Uxbridge, UK;13. Biostatistics, Amgen Inc, Thousand Oaks, CA, USA;14. Clinical Development, Amgen (Europe) GmbH, Munich, Germany;15. UOC Ematologia, Ospedale dell’Angelo, Mestre-Venezia, Italy
Abstract:
Keywords:acute lymphoblastic leukaemia  clinical trials
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号